Share on StockTwits

NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 2,550 shares of the stock on the open market in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $13.06, for a total transaction of $33,303.00. Following the sale, the president now directly owns 123,447 shares in the company, valued at approximately $1,612,218. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NxStage Medical (NASDAQ:NXTM) traded up 1.56% during mid-day trading on Thursday, hitting $13.01. 311,181 shares of the company’s stock traded hands. NxStage Medical has a 52-week low of $8.77 and a 52-week high of $15.65. The stock’s 50-day moving average is $13.41 and its 200-day moving average is $13.31. The company’s market cap is $804.4 million.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was up 13.3% on a year-over-year basis. On average, analysts predict that NxStage Medical will post $-0.45 earnings per share for the current fiscal year.

A number of research firms have recently commented on NXTM. Analysts at Piper Jaffray raised their price target on shares of NxStage Medical from $16.00 to $18.00 in a research note on Friday, August 8th. Analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating and one has assigned a buy rating to the company. NxStage Medical currently has a consensus rating of “Hold” and a consensus target price of $18.25.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.